Merck (MRK) Intangibles (2009 - 2026)
Merck (MRK) posted quarterly Intangibles of $25.7 billion for Q1 2026, up 63.38% year-over-year from $15.8 billion in Q1 2025, and down 3.51% quarter-over-quarter from $26.7 billion in Q4 2025.
Merck (MRK) Intangibles (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Intangibles for 18 consecutive years, with $25.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 63.38% year-over-year to $25.7 billion; the TTM figure through Mar 2026 stood at $25.7 billion (up 63.38% YoY), while the FY2025 annual figure was $26.7 billion, up 62.99% from the prior year.
- Intangibles retreated to $25.7 billion in Q1 2026 per MRK's latest filing, from $26.7 billion in the prior quarter.
- Across five years, Intangibles topped out at $26.7 billion in Q4 2025 and bottomed at $15.2 billion in Q2 2025.
- Historically, Intangibles has averaged $19.4 billion across 5 years, with a median of $19.2 billion in 2023.
- Annual changes were most pronounced in 2022 — Intangibles soared 65.15% — and 2023, when it retreated 13.75%.
- Merck's Intangibles stood at $20.3 billion in 2022, then slipped by 11.14% to $18.0 billion in 2023, then retreated by 9.11% to $16.4 billion in 2024, then surged by 62.99% to $26.7 billion in 2025, then declined by 3.51% to $25.7 billion in 2026.
- Business Quant data shows MRK's Intangibles at $25.7 billion in Q1 2026, $26.7 billion in Q4 2025, and $15.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.98 Bn |
| Mar 31, 2026 | 25.75 Bn |
| Dec 31, 2025 | 26.68 Bn |
| Sep 30, 2025 | 15.31 Bn |
| Jun 30, 2025 | 15.19 Bn |
| Mar 31, 2025 | 15.76 Bn |
| Dec 31, 2024 | 16.37 Bn |
| Sep 30, 2024 | 17.01 Bn |
| Jun 30, 2024 | 16.98 Bn |
| Mar 31, 2024 | 17.57 Bn |
| Dec 31, 2023 | 18.01 Bn |
| Sep 30, 2023 | 19.20 Bn |
| Jun 30, 2023 | 19.67 Bn |
| Mar 31, 2023 | 19.86 Bn |
| Dec 31, 2022 | 20.27 Bn |
| Sep 30, 2022 | 21.37 Bn |
| Jun 30, 2022 | 22.50 Bn |
| Mar 31, 2022 | 23.02 Bn |
| Dec 31, 2021 | 22.93 Bn |
| Sep 30, 2021 | 13.38 Bn |